Loading…
Employees: 1,022
Size Peijia Medical (9996.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $340M, the 858th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$3.94 on 6 Nov 2026.
Performance Over six months the shares fell 34.0%, against -6.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 21.2% over the last twelve months (peer median +5.3%); the operating margin is -13.3% (peer median 4.9%).
Valuation It trades at 335.5× forward earnings against a peer median of 15.3× (most expensive of 9).
Capital Return on invested capital runs 14.2 points below its cost of capital (9.2% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$877M | HK$773M | HK$667M | HK$487M | HK$292M |
| Revenue growth | — | +16% | +37% | +67% | — |
| Gross profit | HK$580M | HK$483M | HK$433M | HK$335M | HK$185M |
| EBITDA | -HK$36.0M | -HK$160M | -HK$206M | -HK$433M | -HK$612M |
| Net income | -HK$155M | -HK$220M | -HK$246M | -HK$434M | -HK$474M |
| Free cash flow | -HK$90.5M | -HK$262M | -HK$247M | -HK$845M | -HK$592M |
| Capital expenditure | HK$205M | HK$330M | HK$304M | HK$349M | HK$235M |
| Total debt | n/a | HK$495M | HK$270M | HK$258M | HK$148M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9996.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.2% | -4.0% | 3rd lowest of 21 |
| 6-month return | -34.0% | -6.8% | 3rd lowest of 20 |
| Distance from 52-week high | -46.5% | -27.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +21.2% | +5.3% | 5th highest of 21 |
| Operating margin | -13.3% | 4.9% | 7th lowest of 21 |
| Forward P/E | 335.5× | 15.3× | most expensive of 9 |
| ROIC minus cost of capital | -14.2 pp | -3.7 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 10.7× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | n/a | 26.0% | -11.9% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |